Chemical Research in Chinese Universities ›› 2015, Vol. 31 ›› Issue (6): 936-941.doi: 10.1007/s40242-015-5202-3

• Articles • Previous Articles     Next Articles

Synthesis, Characterization and Biological Activity of Tetrahydrobenzo[4,5]thieno[2,3-d]pyrimidine Derivatives asEpidermal Growth Factor Receptor Inhibitors

SUN Bing1, YIN Xiu'e1, ZHANG Jin2, HUANG Jian1,2, XU Yue1, ZHANG Furong1, WANG Jinhui1,2, WANG Guoqing1, HU Chun1   

  1. 1. Key Laboratory of Structure-based Drug Design & Discovery, Ministry of Education, School of Pharmaceutical Engineering, Shenyang Pharmaceutical University, Shenyang 110016, P. R. China;
    2. School of Traditional Chinese Materia Medica, Shenyang Pharmaceutical University, Shenyang 110016, P. R. China
  • Received:2015-05-20 Revised:2015-08-27 Online:2015-11-01 Published:2015-09-14
  • Contact: HU Chun E-mail:chunhu@syphu.edu.cn
  • Supported by:

    Supported by the National Natural Science Foundation of China(No.21342006) and the Program for the Innovative Research Team of the Ministry of Education of China(No.IRT_14R36).

Abstract:

Based on the molecular docking studies, which were performed to position Erlotinib and the target compounds into the active site of the epidermal growth factor receptor(EGFR) to determine the probable binding model, a novel series of 5,6,7,8-tetrahydrobenzo[4,5]thieno[2,3-d]pyrimidine derivatives as the novel potential EGFR kinase inhibitors was designed and synthesized. The antitumor activity of all the target compounds against human pulmonary carcinoma cell line A549 has been screened. Of all the target compounds, 4-[2-(1-piperidyl)carbonylmethoxyl- phenthio]-5,6,7,8-tetrahydrobenzo[4,5]thieno[2,3-d]pyrimidine(7j) demonstrated the most potent antitumor activity. Several of the target compounds exhibited moderate antitumor activity. The preliminary structure-activity relationships of some target compounds were summarized.

Key words: Antitumor activity, Docking, Epidermal growth factor receptor(EGFR)